Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab versus placebo in patients with ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are naïve to TNF antagonist therapy https://www.kusajili.fr:443/Trial/IfNGakiJj0WUfNkvL5tVYg%24a-ph-iiiii-seamless-multi-center-randomized-double-blind-placebo-controlled-study-of-the-reduction-in-signs-and-symptoms-and-in
I have read and accept the terms of use of the site and the Privacy Policy
Send your message